常玉医疗器材有限公司.ppt

1、常玉醫療器材有限公司 Champ Medics Co., Ltd. 報告人:華子玲,Asahi Hemofilter 產品介紹,Company Introduction History Manufacturing & Quality Control R&D Membrane Used Biocompability Comparison General Specification Detail Specification Indication of CRRT Clinical Report NHI Reimbursement,About Asahi Medical Co., Ltd.,Asahi

2、 Medical is a world leader in research, development, and production of devices and systems for blood treatment and purification based on advanced membrane separation and adsorption technologies. It serves the global market with dialysis products, plasma therapy products, and blood transfusion produc

3、ts for medical therapy in many countries.The Asahi Medical tradition of leadership in membrane and related blood treatment technologies spans several decades of dedicated and continuing research and development that draw and build on the fundamental strengths of its parent company in fibers, biotech

4、nology, and other materials and process technologies. Asahi Medical was founded in 1974 as a wholly owned subsidiary of Asahi Kasei Corporation. In the same year, it introduced the worlds first cuprammonium rayon hollow-fiber dialyzer, a product of hollow-fiber development begun three years earlier

5、in Asahi Kasei Corporation.The tradition has grown throughout the following decades, based on continuing research and development, experience and service, and expertise in the characteristics and effects of blood treatment with membranes and other separation systems. Now, as always, it is dedicated

6、to serving and advancing medical therapy, for the preservation and enhancement of human life.,Asahi Medical Co., Ltd. - History,Asahi Kasei Group,As a key member of the Asahi Kasei Group and a subsidiary of Asahi Kasei Corporation, Asahi Medical benefits directly from their multidisciplinary knowled

7、ge, expertise, and resources in research and development, materials production and supply, and product and system technologies.Asahi Kasei Corporation is one of Japans largest, most diversified conglomerates. Its fields of operation range from chemicals, fibers, and performance plastics, to housing,

8、 leading-edge electronics, and pharmaceuticals development and production, providing an unsurpassed base and background of experience, knowledge, and expertise for Asahi Medical.,Control at every phase of production Most of our production materials originate either within Asahi Medical itself or the

9、 Asahi Kasei Group, facilitating close, effective control of our products and processes, and the assurance of product reliability for customers worldwide. State-of-the-art manufacturing processes To provide products of the highest quality and performance and to keep abreast of the increasing global

10、demand for these products, Asahi Medical has constantly advanced the process technologies and expanded the production capacities of its plants, located at Oita and Nobeoka Cities in southern Japan, and its production is highly automated, from starting materials to finished products. Strict quality c

11、ontrol as a key commitment Strict quality control is performed at each production stage to ensure high standards and comply with Good Manufacturing Practice and ISO 9001/EN46001. Asahi Medical was one of the first Japanese medical device manufacturers to obtain the CE Mark qualification. Asahi Medic

12、al will continually strive to maintain and improve safety and efficacy, in all current and future products,Asahi Medical Co., Ltd. - Manufacturing & Quality Control,Asahi Medical Co., Ltd. - R & D,Core Competence Blood-related polymers and materials Therapeutic membranes technologyNonwoven filters t

13、echnologyAdsorption technologyBlood/materials interaction analysis technology Blood analysis Fluid, minute-concentration, and stable circulation technologies Extracorporeal therapy and device technologies,Fields of Application Extracorporeal therapyTransfusion blood treatmentSurgical blood treatment

14、Diagnostic blood treatmentBlood cell treatmentBlood related materials,Membrane-Type Cupr Rayon Polysulfone (PS) PAN,USE HD HFD-HDF HFD-HDF,II. Membrane Used,III. Biocompability Comparsion,VII. Indication of C.R.R.T.,Indications of CRRT During SIRS a modification of MODS and MOF develops and within t

15、heir framework the kidney may or may not be affected. Also, in conditions without renal affection,CRRT is fully indicated for eliminating inflammatory mediators that damage other organs. Therefore, the indications for CRRT are divided into renal and non-renal. In MODS with renal failure, both indica

16、tions are interconnected. Renal indications They are obvious from the term. The main indication is oliguric renal failure, in which it is possible to eliminate by CRRT fluid in renal hyperhydration and create more space for parenteral nutrition and drug administration. Balancing takes place as requi

17、red evenly throughout 4 hours. At the same time a stable milieu interieur is maintained and urea, creatinine, uraemic toxins and cytokines are eliminated evenly. Non-renal indications This group comprises: congestive heart failure not responding to diuretics patients with sepsis, septic shock with M

18、ODS and MOF patients with progressing SIRS before development of MODS and MOF some intoxications refractory shifts of the milieu interieur (ions, ABR) ARDS (adult respiratory distress syndrome) - refractory hyperpyrexia - prevention of the tumour-lysis syndrome,VII. Molecular weight of Inflammatory Mediator,IV. General Specification,V. Detail Specification,VI. Clinical Report-1,VI.Clinical Report-2,Note：PAN06 at Takeyama Hospital, Tokyo PAN10 at Sapporo Medical College Fuso Pharmaceutical, Japan Contents: Na ：140 mEq/ L, K： 2.0 mEq/ L